Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis

Critical Care Medicine

Volumn 38, Issue 9, 2010, Pages 1773-1785

  Kumar, Anand ^a,b   Zarychanski, Ryan ^a   Light, Bruce ^a   Parrillo, Joseph ^b   Maki, Dennis ^c   Simon, Dave ^d   Laporta, Denny ^e   Lapinsky, Steve ^f   Ellis, Paul ^g   Mirzanejad, Yazdan ^h   Martinka, Greg ⁱ   Keenan, Sean ^j   Wood, Gordon ^k   Arabi, Yaseen ^l   Feinstein, Daniel ^m   Kumar, Aseem ⁿ   Dodek, Peter ^k   Kravetsky, Laura ^a   Doucette, Steve ^o  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Department of Anesthesiology   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d RUSH UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h SURREY MEMORIAL HOSPITAL   (Canada)

ⁱ Richmond General Hospital   (Canada)

^j ROYAL COLUMBIAN HOSPITAL   (Canada)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^m MOSES H CONE MEMORIAL HOSPITAL   (United States)

ⁿ LAURENTIAN UNIVERSITY   (Canada)

^o OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

more..

Author keywords

antibiotic; combination; monotherapy; mortality; sepsis; septic shock

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; HYPERTENSIVE FACTOR; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; COMBINATION CHEMOTHERAPY; COMMUNITY HOSPITAL; COMPARATIVE STUDY; DRUG MECHANISM; EVALUATION; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; IN VITRO STUDY; INOTROPISM; INTENSIVE CARE UNIT; ISOLATION PROCEDURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVAL RATE; THERAPY EFFECT; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VENTILATOR; AGED; DRUG COMBINATION; MICROBIOLOGY; MIDDLE AGED; PROPENSITY SCORE; SHOCK, SEPTIC;

AGED; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77956226360     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181eb3ccd     Document Type: Article

References (66)

1. McCabe WR, Jackson GG: Gram-negative bacteremia II. Clinical, laboratory and therapeutic observations. Arch Intern Med 1962; 110:856-864.
2. Kreger BE, Craven DE, McCabe WR: Gramnegative bacteremia IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68:344-355.
3. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474.
4. Parkins MD, Sabuda DM, Elsayed S, et al: Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60:613-618.
5. Kumar A, Ellis P, Arabi Y, et al: Initiation of inappropriate antimicrobial therapy results in a five-fold reduction of survival in human septic shock. Chest 2009; 136:1237-1248.
6. Chow JW, Yu VL: Combination antibiotic therapy versus monotherapy for gramnegative bacteraemia: A commentary. Int J Antimicrob Agents 1999; 11:7-12.
7. Mufson MA, Stanek RJ, Mufson MA, et al: Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia. Clin Infect Dis 2006; 42:304-306.
8. Patel SM, Saravolatz LD: Monotherapy versus combination therapy. Med Clin North Am 2006; 90:1183-1195.
9. Paul M, Leibovici L: Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005; 5:192-193.
10. Weiss K, Tillotson GS: The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005; 128:940-946.
11. Anderson ET, Young LS, Hewitt WL: Antimicrobial synergism in the therapy of Gramnegative rod bacteremia. Chemotherapy 1978; 24:45-54.
12. De Jongh CA, Joshi JH, Newman KA, et al: Antibiotic synergism and response in gramnegative bacteremia in granulocytopenic cancer patients. Am J Med 1986; 80:96-100.
13. Bouza E, Munoz P: Monotherapy versus combination therapy for bacterial infections. Med Clin North Am 2000; 84:1357-1389.
14. Darras-Joly C, Bedos JP, Sauve C, et al: Synergy between amoxicillin and gentamicin in combination against a highly penicillinresistant and-tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 1996; 40:2147-2151.
15. Calandra T, Glauser MP: Immunocompromised animal models for the study of antibiotic combinations. Am J Med 1986; 80:45-52.
16. Kumar A, Mensing J, Zelenitsky S, et al: Effect of antibiotic sequence on blood bacterial counts in a rat model of E. coli peritonitis/septic shock. ICAAC Proceedings, 2004, pp 26, A-1296.
17. Safdar N, Handelsman J, Maki DG, et al: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-527.
18. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al:-lactam monotherapy versus-lactamaminoglycoside combination therapy for sep-sis in immunocompetent patients: Systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668-679.
19. Kumar A, Safdar N, Reddy S, et al: The survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/metaregression study. Crit Care Med 2010; 38: 1651-1664.
20. Bone RC, Balk R, Cerra FB, et al: ACCP/SCCM Consensus Conference: Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Chest 1992; 101:1644-1655.
21. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596.
22. McGeer A, Campbell B, Emori TG, et al: Definitions of infection for surveillance in long-term care facilities. Am J Infect Control 1991; 19:1-7.
23. Garner JS, Jarvis WR, Emori TG, et al: CDC definitions for nosocomial infections,. Am J Infect Control 1988; 16:128-140.
24. Zarychanski R, Doucette S, Fergusson D, et al: Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973-2979.
25. Bagshaw SM, Lapinsky S, Dial S, et al: Acute kidney injury in septic shock: Clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009; 35:871-881.
26. Knaus WA, Draper EA: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829.
27. Glynn RJ, Schneeweiss S, Sturmer T: Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98:253-259.
28. Luellen JK, Shadish WR, Clark MH: Propensity scores: An introduction and experimental test. Eval Rev. 2005; 29:530-558.
29. Parsons LS: SUGI 26: Reducing Bias in a Propensity Score Matched-pair Sample Using Greedy Matching Techniques, SAS Institute, Cary, NC, 2001.
30. Suissa S: Immortal time bias in observational studies of drug effects Pharmacoepidemiol Drug Saf 2007; 16:241-249.
31. Breslow NE, Day NE: Statistical methods in cancer research. Analysis of case-control studies.
32. Lyon, France, International Agency for Research on Cancer, IARC Scientific Publications No. 32, 1980, pp 138-146.
33. Bochud PY, Glauser MP, Calandra T, et al: Antibiotics in sepsis, Intensive Care Med 2001; 27(Suppl 1):S33-S48.
34. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock:. Crit Care Med 2008; 36:296-327.
35. Gribble MJ, Chow AW, Naiman SC, et al: Prospective randomized trial of piperacillin monotherapy versus carboxypenicillinaminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 1983; 24:388-393.
36. EORTC International Anti-microbial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987; 317:1692-1698.
37. Milatovic D, Braveny I: Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6:234-244.
38. Pasquale TR, Tan JS: Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005; 40:127-135.
39. Labro MT: Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Micro Rev 2000; 13:615-650.
40. De Jongh CA, Joshi JH, Thompson BW, et al: A double-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1986; 80: 101-111.
41. Klastersky J, Zinner SH: Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982; 4:294-301.
42. Giamarellou H: Aminoglycosides plus betalactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986; 80:126-137.
43. Guchelaar HJ, Schultz MJ, van D, et al: Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production. Fund Clin Pharmacol 2001; 15: 419-424.
44. Labro MT: Cellular and molecular effects of macrolides on leukocyte function. Curr Pharm Des 2004; 10:3067-3080.
45. Khan AA, Slifer TR, Araujo FG, et al: Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11:121-132.
46. Oda H, Kadota J, Kohno S, et al: Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106:1116-1123.
47. Khan AA, Slifer TR, Remington JS: Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob Agents Chemother 1998; 42:1713-1717.
48. Goscinski G, Lundholm M, Odenholt I, et al: Variation in the propensity to release endotoxin after cefuroxime exposure in different gram-negative bacteria: Uniform and dosedependent reduction by the addition of tobramycin. Scand J Infect Dis 2003; 35:40-46.
49. Goscinski G, Lipcsey M, Eriksson M, et al: Endotoxin neutralization and anti-inflammatory effects of tobramycin and ceftazidime in porcine endotoxin shock. Crit Care 2004; 8:R35-R41.
50. Comber KR, Basker MJ, Osborne CD, et al: Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob Agents Chemother 1977; 11:956-964.
51. Archer G, Fekety FR Jr: Experimental endocarditis due to Pseudomonas aeruginosa II. Therapy with carbenicillin and gentamicin. J Infect Dis 1977; 136:327-335.
52. Yoshikawa TT, Shibata SA: In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1978; 13:997-999.
53. Kluge RM, Standiford HC, Tatem B, et al: Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1974; 6:442-446.
54. Gimeno C, Borja J, Navarro D, et al: In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections. Chemotherapy 1998; 44:94-98.
55. Gradelski E, Kolek B, Bonner DP, Valera L, et al: Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int J Antimicrob Agents 2001; 17: 103-107.
56. Zembower TR, Noskin GA, Postelnick MJ, et al: The utility of aminoglycosides in an era of emerging drug resistance. Int J Antimicrob Agents 1998; 10:95-105.
57. Neu HC: Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs 1993; 45(Suppl 3):54-58.
58. Pohlman JK, Knapp CC, Ludwig MD, et al: Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. Diagnostic Microbiol Infect Dis 1996; 26:29-33.
59. Milatovic D, Wallrauch C: In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Eur J Clin Microbiol Infect Dis 1996; 15:688-693.
60. Pankuch GA, Lin G, Seifert H, et al: Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52:333-336.
61. Lin E, Stanek RJ, Mufson MA: Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 2003; 47:1151-1153.
62. MacGowan AR, Bowker K, Bedford KA, et al: Synergy testing of macrolide combinations using the chequerboard technique. J Antimicrob Chemother 1993; 32:913-915.
63. Furuya R, Nakayama H, Kanayama A, et al: In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006; 12:172-176.
64. Maioli E, Debbia EA, Gualco L, et al: In vitro interaction between mecillinam and pipera-cillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa. New Microbiol 2008; 31:37-46.
65. Allen NE, Epp JK: Mechanism of penicillinerythromycin synergy on antibiotic-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13:849-853.
66. Connors AF Jr, Speroff T, Dawson NV, et al: The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996; 276:889-897